Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.50 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | CD44 | P16070 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5795490 | 0.98 | PNMT (0.49) | PNMTPRCPBCL2L1BADCD44 | |
| SCHEMBL19684557 | 0.95 | PNMT (0.47) | PNMTPRCPBCL2L1BADCD44 | |
| SCHEMBL11947231 | 0.89 | PNMT (0.61) | PNMTPRCPCD44HTR2CMAOB | |
| SCHEMBL31327524 | 0.89 | PNMT (0.61) | PNMTPRCPCD44HTR2CMAOB | |
| SCHEMBL29750070 | 0.78 | CD44 (0.42) | PNMTPRCPCD44HTR2CMAOB | |
| SCHEMBL5068782 | 0.78 | CD44 (0.42) | PNMTPRCPCD44HTR2CMAOB | |
| SCHEMBL11327500 | 0.78 | PNMT (0.50) | PNMTPRCPCD44HTR2CMAOB | |
| SCHEMBL11331868 | 0.78 | PNMT (0.79) | PNMTPRCPCD44HTR2C | |
| SCHEMBL11597488 | 0.78 | BCL2L1 (0.60) | PNMTPRCPBCL2L1BADCD44 | |
| SCHEMBL14692360 | 0.78 | PNMT (0.50) | PNMTPRCPCD44HTR2CMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | PNMT 2003/4885PRCP 664/4885BCL2L1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.